Apr. 24 at 2:00 PM
$RADX ((data in June))
Strong data (≈90%) ✅ your base case
What it means:
Clearly better than MRI
Clinically meaningful differentiation
Opens door to:
Acquisition
Fast-track Phase 3
Valuation logic:
RAD101 =
$400–600M asset
Add small therapeutic optionality
👉 Market cap:
$300–500M
👉 Stock price:
$25 –
$42
$AKTS $CATX
